Proteomic Analysis of Human Scleroderma Fibroblasts Response to Transforming Growth Factor‐ß

Abstract

That the proteome of fibroblasts differs between SSc patients and HC is confirmed, and it is demonstrated that fibroblasts exacerbate their proteomic phenotype upon stimulation with TGF-ß. EGFR and Pi3K are highlighted as proteins of interest in SSc fibroblasts.

Candidate proteomic biomarkers in systemic sclerosis discovered using mass-spectrometry: an update of a systematic review (2014–2020)

“…After full text analysis, two articles were excluded due to the fact that they did not present exploratory proteomic studies, and two articles used SOMASCAN method. Therefore in the end 9 articles had their information retrieved in the database (Figure 1) [6][7][8][9][10][11][12][13][14].…”

“…Chaigne et al, [12] Cutaneous fibroblast cell culture supernatant 4 dSsc/3 unmatched healthy controls 2DE-DIGE/MALDI-TOF MS controls Schiller et al, [14] Pulmonary biopsy 45 endstage Ssc with ILD/ 10 healthy controls LC-MS/MS Table 2 : Summarization of included articles (biological sample, sample size and proteomic technique) ILD: interstitial lung disease, dSsc-diffuse systemic sclerosis, lSsc-localized systemic sclerosis, 2DE-two dimension electrophoresis, 2DE-DIGE-two-dimension electrophoresis fluorescence difference gel electrophoresis, MALDI-Matrix-assisted laser desorption/ionization, LC-MS/MS-Liquid chromatography -mass spectrometry , TOF-Time of flight, SELDI-TOF-MS-surface enhanced laser desorption/ionization-time of flight mass spectrometry…”

“…Most studies included healthy matched controls (for gender and age (8/9 studies) and one study clearly stated that healthy controls were not matched with Ssc patients [12]. Matching is very important because some biomarkers are known to have gender and age variation and differences can rise only from the fact that controls were not matched with Ssc cases.…”

“…Myelin basic protein (-4.05) , Solute carrier family 35-member E2B (-2.17), Carboxypeptidase B2 (-1.83), Plasma serine protease inhibitor (-1.44), Protein BCAP (-1.27), Tallin-1 (-0.91), Complement C2 (0.67), Fibrinogen gamma chain (0.73), Fibrinogen beta chain (0.73), Fibrinogen alpha chain (0.81), Alpha- Corallo et al, [8] 37 biomarkers (26 upregulated, 7 downregulated, Chaigne et al, [12] 42 biomarkers (17 upregulated, Chairta P et al, [10] 132 biomarkers (69 upregulated; (2,18); Clusterin (1,96); Cytochrome C Oxidase Subunit 6B1 (5,26); Carboxypeptidase N Subunit 2 (1,66); Cytochrome C1(0,58); Cytochrome P450 Family 4 Subfamily F Member 22 (0,59); Drebrin 1 (1,90); Dermcidin (1,66); DEAD-Box Helicase 55 (3,33); Deoxyribose-Phosphate Aldolase (0,59); Dehydrogenase/Reductase 7 (0,51); DEAH-Box Helicase 15 (0,61); Dermatopontin (1,88); Dynein Cytoplasmic 1 Light Intermediate Chain 2 (1,55); Eukaryotic Translation Initiation Factor…”

“…Identification and description of clinical question (9/9) All articles included in the analysis Assessment of subject description (8/9) Ryu et al, [6] Landi et al, [7] , van Bon et al, [9], Chairta et al, [10], Mullenbrock et al, [11], Chaigne et al, [12], Dumi et al [13], Schiller et al, [14] Sampling description (9/9) All articles included in the analysis Presentation of experimental methodology (9/9) All articles included in the analysis Statistical approach (9/9) All articles included in the analysis Validation of results 5/9Landi et al, [7] (WB), Corallo et al, [8] (IHC), van Bon et al, [9] (ELISA), Chairta et al, [10] (MRM), Schiller et al, [14] (WB) Limitation acknowledgement 2/9Ryu et al, [6], Chaigne et al, [12] Clear presentation of each authors' contribution (5/9)…”